On August 20, Hims & Hers Health Inc. rose 5.21% in regular trading, trading at $32.71/share, with turnover of $80.25 million. The stock extended its rebound as CEO Andrew Dudum's public defense against the FTC lawsuit continued to lift investor confidence.

Dudum appeared on CNBC to respond to the FTC's allegations that the company shared user health data with Meta and Snap, charged fees improperly, and created obstacles to subscription cancellations. He characterized the accusations as stemming from misunderstandings of the company's business model, emphasizing that Hims & Hers is an \"aggressive disruptor\" focused on expanding healthcare accessibility. The company has maintained that the lawsuit ignores substantial evidence submitted during nearly three years of investigation.

The management's assertive stance has progressively eased market concerns since the FTC filing on July 30 initially triggered a 12% drop. Analyst upgrades have provided additional support, with Needham raising its target price to $42 and Morgan Stanley lifting its target to $28 from $21 while maintaining an Equalweight rating.

Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals, enabling access to medical care for mental health, sexual health, dermatology and primary care.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)